BTK Inhibitor Plus Immunotherapy Shows Durable Responses in Relapsed CNS Lymphoma
A prospective phase II trial reports that orelabrutinib combined with sintilimab achieved a 60.7 percent response rate and a median ...
Tag: orelabutinib
POPULAR NEWS
-
Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant
-
Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast
-
ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth
-
Systematic review maps sustainability tensions in offshore wind development